Search company, investor...

GlycoVaxyn

glycovaxyn.com

Founded Year

2004

Stage

Corporate Majority | Acquired

Total Raised

$30.6M

Valuation

$0000 

About GlycoVaxyn

GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology. GlycoVaxyn's technology enables the development and production of immunogenic glycoproteins (polysaccharide and protein complexes) for use as conjugated vaccines.

Headquarters Location

Grabenstrasse 3

Schlieren, 8952,

Switzerland

+41 44 733 85 85

Missing: GlycoVaxyn's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: GlycoVaxyn's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

GlycoVaxyn Patents

GlycoVaxyn has filed 1 patent.

The 3 most popular patent topics include:

  • Vaccines
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/13/2014

1/11/2022

Molecular biology, Genetics, Biotechnology, Transcription factors, Gene expression

Grant

Application Date

10/13/2014

Grant Date

1/11/2022

Title

Related Topics

Molecular biology, Genetics, Biotechnology, Transcription factors, Gene expression

Status

Grant

Latest GlycoVaxyn News

BRIEF—LimmaTech targets first gonorrhea vaccine with licensing deal

Oct 24, 2022

Swiss vaccines company LimmaTech Biologics has announced a license and collaboration agreement with Griffith University in Queensland, Australia. LimmaTech—which was spun out from GlycoVaxyn after its $190 million acquisition by UK pharma major GSK—has obtained an exclusive license to a suite of vaccine technologies developed by Michael Jennings and Kate Seib at Griffith University’s Institute for Glycomics. Technologies will be initially applied, alongside LimmaTech’s in-house expertise, to develop what would be the world’s first vaccine against gonorrhea, the second most common sexually transmitted disease worldwide. Michael Kowarik, chief scientific officer of LimmaTech, said: “Antibiotic resistance and rising rates of gonorrhoea infections worldwide demonstrate the need for a gonococcal vaccine that can protect against potentially life-threatening variants. Antibodies against our antigens are functionally active in a variety of relevant assays, demonstrating promising vaccine efficacy. “Our collaboration with Griffith University will enable us to develop a much-needed vaccination option to address gonorrhoea and to advance other new vaccines for rapidly evolving global challenges.”

GlycoVaxyn Frequently Asked Questions (FAQ)

  • When was GlycoVaxyn founded?

    GlycoVaxyn was founded in 2004.

  • Where is GlycoVaxyn's headquarters?

    GlycoVaxyn's headquarters is located at Grabenstrasse 3, Schlieren.

  • What is GlycoVaxyn's latest funding round?

    GlycoVaxyn's latest funding round is Corporate Majority.

  • How much did GlycoVaxyn raise?

    GlycoVaxyn raised a total of $30.6M.

  • Who are the investors of GlycoVaxyn?

    Investors of GlycoVaxyn include GSK, Sofinnova Partners, Medicxi Ventures and Andera Partners.

  • Who are GlycoVaxyn's competitors?

    Competitors of GlycoVaxyn include Pulmotect, Intralytix, GangaGen, Bloomage BioTech, Sharklet Technologies and 11 more.

Compare GlycoVaxyn to Competitors

Pulmotect Logo
Pulmotect

Pulmotect is a biopharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.

G
GangaGen

GangaGen is a biotechnology company focused on the development of products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences.

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

A
AviGenics

Avigenics is a company that received a SBIR Phase I grant for a project entitled: Production of Transgenic Poultry Resistant to Avian Influenza Infection by RNAi. Their project generates transgenic poultry resistant to avian influenza (AI) virus through RNA interference (RNAi) technology. Poultry are vulnerable to AI infections that can rapidly reach mortality rates approaching 100%. Current vaccines provide only limited protection, with prophylaxis based on surveillance and diagnosis, followed by rapid depopulation and disposal of infected or exposed birds and quarantine and disinfection of farms and equipment. RNAi technology is a new strategy that could be applied to the inhibition of AI virus replication, representing a paradigm shift in the way to deal with the challenges of AI. Phase I objectives are (i) to generate ALV vectors hosting short interfering RNA (siRNA), (ii) establish stable cell lines hosting siRNAs vectors and (iii) test the efficacy of siRNAs against AI viruses. Three siRNAs shown to effectively inhibit AI viruses will be used to generate cell lines, which will be challenged with 5 different AI viruses to determine whether these vectors, when integrated into the avian genome, can effectively inhibit AI viruses. The broader impact of this research will be to improve the biosecurity of biopharmaceutical production in poultry as the avian influenza virus spreads and well as potentially protecting the food supply from natural as well as bioterrorist threats should these transgenic chickens gain wide approval in the marketplace.

Intralytix Logo
Intralytix

Intralytix is a biotechnology company focused on the discovery, production, and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.